Source comparison
PT-141 Dosage Erectile Function 2026: Comparison Table
0.5 45–55% +1.2 6% 50–70 Subtherapeutic. Insufficient MC4R activation for consistent arousal pathway stimulation 1.0 70–80% +3.1 11% 45–60 Threshold dose. Effective in MC4R-sensitive individuals but underdosed for most subjects 1.5 85–90% +4.8 18% 40–50 Optima
This comparison does not assign a generated winner or score.
- 0.5
- 45–55%
- +1.2
- 6%
- 50–70
- Subtherapeutic. Insufficient MC4R activation for consistent arousal pathway stimulation
- 1.0
- 70–80%
- +3.1
- 11%
- 45–60
- Threshold dose. Effective in MC4R-sensitive individuals but underdosed for most subjects
- 1.5
- 85–90%
- +4.8
- 18%
- 40–50
- Optimal dose. Maximal efficacy with acceptable tolerability; plateau of receptor saturation curve
- 2.0
- 92–95%
- +5.1
- 34%
- 35–45
- Marginal efficacy gain (+0.3 points) at cost of doubled nausea incidence. Not justified
- 2.5
- 96–98%
- +5.2
- 52%
- 30–40
- Excessive. Adverse events outweigh negligible efficacy improvement; receptor occupancy ceiling reached